Redirection of CD4+ and CD8+ T lymphocytes via an anti-CD3 × anti-CD19 bi-specific antibody combined with cytosine arabinoside and the efficient lysis of patient-derived B-ALL cells

Journal of Hematology and Oncology

Volumn 8, Issue 1, 2015, Pages

  Fan, Dongmei ^a   Li, Wei ^b   Yang, Yuqi ^b   Zhang, Xiaolong ^a   Zhang, Qing ^a   Yan, Yan ^a   Yang, Ming ^a   Wang, Jianxiang ^a   Xiong, Dongsheng ^a  

^a INSTITUTE OF HEMATOLOGY AND BLOOD DISEASES HOSPITAL   (China)

^b TIANJIN MEDICAL UNIVERSITY   (China)

Author keywords

Anti CD19; B ALL; Bi specific antibody; Cancer immunotherapy; Diabody anti CD3; Disulfide crosslinks

Indexed keywords

B7 ANTIGEN; CD19 ANTIBODY; CD3 ANTIBODY; CD3 CD19 BISPECIFIC ANTIBODY; CD86 ANTIGEN; CYTARABINE; DIABODY; GAMMA INTERFERON; GRANZYME B; INTERLEUKIN 2; INTERLEUKIN 3; INTERLEUKIN 6; PERFORIN; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; BISPECIFIC ANTIBODY; CD19 ANTIGEN; CD3 ANTIGEN; CYTOKINE; GRANZYME;

ACUTE LYMPHOBLASTIC LEUKEMIA; ANTIBODY SPECIFICITY; ANTIGEN EXPRESSION; ARTICLE; B ACUTE LYMPHOBLASTIC LEUKEMIA; B-CELL LEUKEMIA CELL LINE; CANCER COMBINATION CHEMOTHERAPY; CANCER INHIBITION; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE RELEASE; DRUG CYTOTOXICITY; DRUG POTENTIATION; DRUG SENSITIVITY; DRUG TARGETING; HUMAN; HUMAN CELL; IMMUNOMODULATION; IN VITRO STUDY; IN VIVO STUDY; LOW DRUG DOSE; LYSIS; T LYMPHOCYTE ACTIVATION; T LYMPHOCYTE SUBPOPULATION; UPREGULATION; ANIMAL; CELL CULTURE; CYTOTOXICITY; DRUG EFFECTS; DRUG SCREENING; FLOW CYTOMETRY; GENE EXPRESSION REGULATION; GENETICS; IMMUNOLOGY; LYMPHOCYTE ACTIVATION; METABOLISM; NONOBESE DIABETIC MOUSE; PRECURSOR B-CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SCID MOUSE; TUMOR CELL CULTURE; TUMOR CELL LINE; TUMOR VOLUME;

ANIMALS; ANTIBODIES, BISPECIFIC; ANTIGENS, CD19; ANTIGENS, CD3; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CELL LINE, TUMOR; CELLS, CULTURED; CYTARABINE; CYTOKINES; CYTOTOXICITY, IMMUNOLOGIC; FLOW CYTOMETRY; GENE EXPRESSION REGULATION, LEUKEMIC; GRANZYMES; HUMANS; LYMPHOCYTE ACTIVATION; MICE, INBRED NOD; MICE, SCID; PERFORIN; PRECURSOR B-CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TUMOR BURDEN; TUMOR CELLS, CULTURED; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84942853133     PISSN: None     EISSN: 17568722     Source Type: Journal    
DOI: 10.1186/s13045-015-0205-6     Document Type: Article

References (53)

1. Geethakumari PR, Hoffmann MS, Pemmaraju N, Hu S, Jorgensen JL, O'Brien S, et al. Extramedullary B lymphoblastic leukemia/lymphoma (B-ALL/B-LBL): a diagnostic challenge. Clin Lymphoma Myeloma Leuk. 2014;14:e115-8.
2. Wiegering V, Frank J, Freudenberg S, Morbach H, Schlegel PG, Eyrich M, et al. Impaired B-cell reconstitution in children after chemotherapy for standard or medium risk acute precursor B-lymphoblastic leukemia. Leuk Lymphoma. 2014;55:870-5.
3. Boonchalermvichian C, Xie Y, Brynes RK, Siddiqi IN. Spontaneous, transient regression of B lymphoblastic leukemia in an adult patient: a variant presentation of prodromal/pre-ALL. Leuk Res. 2012;36:e57-9.
4. Faderl S, O'Brien S, Pui CH, Stock W, Wetzler M, Hoelzer D, et al. The biology and therapy of adult acute lymphoblastic leukemia. Cancer. 2010;116:1165-76.
5. Mellman I, Coukos G, Dranoff G. Cancer immunotherapy comes of age. Nature. 2011;480:480-9.
6. Akinleye A, Furqan M, Mukhi N, Ravella P, Liu D. MEK and the inhibitors: from bench to bedside. J Hematol Oncol. 2013;6(1):27.
7. Furqan M, Akinleye A, Mukhi N, Mittal V, Chen Y, Liu D. STAT inhibitors for cancer therapy. J Hematol Oncol. 2013;6(1):90.
8. Zhao Y, Huang H, Wei G. Novel agents and biomarkers for acute lymphoid leukemia. J Hematol Oncol. 2013;6:40.
9. Grover NS, Park SI. Novel Targeted Agents in Hodgkin and Non-Hodgkin Lymphoma Therapy. Pharmaceuticals (Basel). 2015;8:607-36.
10. Suresh T, Lee L, Joshi J, Barta S. New antibody approaches to lymphoma therapy. J Hematol Oncol. 2014;7(1):58.
11. Mellor JD, Brown MP, Irving HR, Zalcberg JR, Dobrovic A. A critical review of the role of Fc gamma receptor polymorphisms in the response to monoclonal antibodies in cancer. J Hematol Oncol. 2013;6:1.
12. Hoelzer D, Gokbuget N. Chemoimmunotherapy in acute lymphoblastic leukemia. Blood Rev. 2012;26:25-32.
13. Kantarjian H, Thomas D, Wayne AS, O'Brien S. Monoclonal antibody-based therapies: a new dawn in the treatment of acute lymphoblastic leukemia. J Clin Oncol. 2012;30:3876-83.
14. Thomas DA, O'Brien S, Faderl S, Garcia-Manero G, Ferrajoli A, Wierda W, et al. Chemoimmunotherapy with a modified hyper-CVAD and rituximab regimen improves outcome in de novo Philadelphia chromosome-negative precursor B-lineage acute lymphoblastic leukemia. J Clin Oncol. 2010;28:3880-9.
15. Hoelzer D. Targeted therapy with monoclonal antibodies in acute lymphoblastic leukemia. Curr Opin Oncol. 2013;25:701-6.
16. Breton CS, Nahimana A, Aubry D, Macoin J, Moretti P, Bertschinger M, et al. A novel anti-CD19 monoclonal antibody (GBR 401) with high killing activity against B cell malignancies. J Hematol Oncol. 2014;7:33.
17. Akinleye A, Chen Y, Mukhi N, Song Y, Liu D. Ibrutinib and novel BTK inhibitors in clinical development. J Hematol Oncol. 2013;6(1):59.
18. Han E, Li X-l, Wang C-r, Li T-f, Han S-y. Chimeric antigen receptorengineered T cells for cancer immunotherapy: progress and challenges. J Hematol Oncol. 2013;6(1):47.
19. Wu J, Fu J, Zhang M, Liu D. AFM13: a first-in-class tetravalent bispecific anti-CD30/CD16A antibody for NK cell-mediated immunotherapy. J Hematol Oncol. 2015;8:96.
20. Wolf E, Hofmeister R, Kufer P, Schlereth B, Baeuerle PA. BiTEs: bispecific antibody constructs with unique anti-tumor activity. Drug Discov Today. 2005;10(18):1237-44.
21. Hoffmann P, Hofmeister R, Brischwein K, Brandl C, Crommer S, Bargou R, et al. Serial killing of tumor cells by cytotoxic T cells redirected with a CD19-/CD3-bispecific single-chain antibody construct. Int J Cancer. 2005;115:98-104.
22. Offner S, Hofmeister R, Romaniuk A, Kufer P, Baeuerle PA. Induction of regular cytolytic T cell synapses by bispecific singlechain antibody constructs on MHC class I-negative tumor cells. Mol Immunol. 2006;43:763-71.
23. Baeuerle PA, Reinhardt C. Bispecific T-cell engaging antibodies for cancer therapy. Cancer Res. 2006;69:4941-4.
24. Stamova S, Feldmann A, Cartellieri M, Arndt C, Koristka S, Apel F, et al. Generation of single-chain bispecific green fluorescent protein fusion antibodies for imaging of antibody-induced T cell synapses. Anal Biochem. 2012;423:261-8.
25. Kipriyanov SM, Moldenhauer G, Strauss G, Little M. Bispecific CD3 x CD19 diabody for T cell-mediated lysis of malignant human B cells. Int J Cancer. 1998;77:763-72.
26. Löffler A, Kufer P, Lutterbüse R, Zettl F, Daniel PT, Schwenkenbecher JM, et al. A recombinant bispecific single-chain antibody, CD19 × CD3, induces rapid and high lymphoma-directed cytotoxicity by unstimulated T lymphocytes. Blood. 2000;95:2098-103.
27. Topp MS, Kufer P, Gökbuget N, Goebeler M, Klinger M, Neumann S, et al. Targeted therapy with the T-cell-engaging antibody blinatumomab of chemotherapy-refractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survival. J Clin Oncol. 2011;29:2493-8.
28. Hu J, Kinn J, Zirakzadeh AA, Sherif A, Norstedt G, Wikström AC, et al. The effects of chemotherapeutic drugs on human monocyte-derived dendritic cell differentiation and antigen presentation. Clin Exp Immunol. 2013;172:490-9.
29. Rummel MJ, Niederle N, Maschmeyer G, Banat GA, von Grünhagen U, Losem C, et al. Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial. Lancet. 2013;381:1203-10.
30. Hiddemann W, Kneba M, Dreyling M, Schmitz N, Lengfelder E, Schmits R, et al. Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood. 2005;106:3725-32.
31. Wei L, Dongmei F, Ming Y, Ruizan S, Yan Y, Linlin J, et al. Disulfide-stabilized diabody antiCD19/antiCD3 exceeds its parental antibody in tumor-targeting activity. Cell Oncol. 2012;35:423-34.
32. Osada T, Hsu D, Hammond S, Hobeika A, Devi G, Clay TM, et al. Metastatic colorectal cancer cells from patients previously treated with chemotherapy are sensitive to T-cell killing mediated by CEA/CD3-bispecific T-cellengaging BiTE antibody. Br J Cancer. 2010;102:124-33.
33. Tretter CP, Lewis LD, Fisher J, Waugh MG, Ernstoff MS. Taxanes synergize with the bispecific antibody MDXH447 to enhance antibody-dependent cell-mediated cytotoxicity. J Chemother. 2003;15:472-9.
34. Li W, Fan D, Yang M, Yan Y, Shi R, Cheng J, et al. Cytosine arabinoside promotes cytotoxic effect of T cells on leukemia cells mediated by bispecific antibody. Hum Gene Ther. 2013;24:751-60.
35. Bassan R, Hoelzer D. Modern therapy of acute lymphoblastic leukemia. J Clin Oncol. 2011;29:532-43.
36. Emens LA. Chemoimmunotherapy. Cancer J. 2010;16:295-303.
37. Vereecque R, Saudemont A, Quesnel B. Cytosine arabinoside induces costimulatory molecule expression in acute myeloid leukemia cells. Leukemia. 2004;18:1223-30.
38. Molldrem JJ, Lee PP, Wang C, Felio K, Kantarjian HM, Champlin RE, et al. Evidence that specific T lymphocytes may participate in the elimination of chronic myelogenous leukemia. Nat Med. 2000;6:1018-23.
39. Rezvani K, Grube M, Brenchley JM, Sconocchia G, Fujiwara H, Price DA, et al. Functional leukemia-associated antigen-specific memory CD8+ T cells exist in healthy individuals and in patients with chronic myelogenous leukemia before and after stem cell transplantation. Blood. 2003;102:2892-900.
40. van der Most RG, Curie A, Cleaver A, Salmons J, Nowak AK, Mahendran S, et al. Cyclophosphamide chemotherapy sensitizes tumor cells to TRAILdependent CD8+ T cell-mediated immune attack resulting in suppression of tumor growth. PLoS One. 2009;4:e6982.
41. Zhu J, Paul WE. CD4 T cells: fates, functions, and faults. Blood. 2008;112:1557-69.
42. Seo N, Tokura Y. Downregulation of innate and acquired antitumor immunity by bystander gammadelta and alphabeta T lymphocytes with Th2 or Tr1 cytokine profiles. J Interferon Cytokine Res. 1999;19:555-61.
43. Krupka C, Kufer P, Kischel R, Zugmaier G, Bögeholz J, Köhnke T, et al. CD33 target validation and sustained depletion of AML blasts in long-term cultures by the bispecific T-cell-engaging antibody AMG 330. Blood. 2014;123:356-65.
44. Laszlo GS, Gudgeon CJ, Harrington KH, Dell'Aringa J, Newhall KJ, Means GD, et al. Cellular determinants for preclinical activity of a novel CD33/CD3 bispecific T-cell engager (BiTE) antibody, AMG 330, against human AML. Blood. 2014;123:554-61.
45. Aigner M, Feulner J, Schaffer S, Kischel R, Kufer P, Schneider K, et al. T lymphocytes can be effectively recruited for ex vivo and in vivo lysis of AML blasts by a novel CD33/CD3-bispecific BiTE antibody construct. Leukemia. 2013;27:1107-15.
46. Kritas SK, Saggini A, Cerulli G, Caraffa A, Antinolfi P, Pantalone A, et al. Interrelationship between IL-3 and mast cells. J Biol Regul Homeost Agents. 2014;28:17-21.
47. Maude SL, Barrett D, Teachey DT, Grupp SA. Managing cytokine release syndrome associated with novel T cell-engaging therapies. Cancer J. 2014;20(2):119-22.
48. Klinger M, Brandl C, Zugmaier G, et al. Immunopharmacologic response of patients with B-lineage acute lymphoblastic leukemia to continuous infusion of T cell-engaging CD19/CD3-bispecific BiTE antibody blinatumomab. Blood. 2012;119:6226-33.
49. Chen L, Flies DB. Molecular mechanisms of T cell co-stimulation and co-inhibition. Nat Rev Immunol. 2013;13:227-42.
50. Shi L, Chen S, Yang L, Li Y. The role of PD-1 and PD-L1 in T-cell immune suppression in patients with hematological malignancies. J Hematol Oncol. 2013;6:74.
51. Lee DW, Barrett DM, Mackall C, et al. The future is now: chimeric antigen receptors as new targeted therapies for childhood cancer. Clin Cancer Res. 2012;18:2780-90.
52. Urbanska K, Lynn RC, Stashwick C, Thakur A, Lum LG, Powell DJ Jr. Targeted cancer immunotherapy via combination of designer bispecific antibody and novel gene-engineered T cells. J Transl Med. 2014;12:347-59
53. Ailles LE, Gerhard B, Kawagoe H, Hogge DE. Growth characteristics of acute myelogenous leukemia progenitors that initiate malignant hematopoiesis in nonobese diabetic/severe combined immunodeficient mice. Blood. 1999;94:1761-72.